Protagonist Therapeutics, Inc.

Informe acción NasdaqGM:PTGX

Capitalización de mercado: US$7.1b

Protagonist Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Protagonist Therapeutics es Dinesh Patel , nombrado en Dec 2008, tiene una permanencia de 17.5 años. compensación anual total es $12.87M, compuesta por 5.6% salario y 94.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.45% de las acciones de la empresa, por valor de $31.56M. La antigüedad media del equipo directivo y de la junta directiva es de 5.4 años y 11.4 años, respectivamente.

Información clave

Dinesh Patel

Chief Executive Officer (CEO)

US$12.9m

Compensación total

Porcentaje del salario del CEO5.56%
Permanencia del CEO17.5yrs
Participación del CEO0.4%
Permanencia media de la dirección5.4yrs
Promedio de permanencia en la Junta Directiva11.4yrs

Actualizaciones recientes de la dirección

Recent updates

Artículo de análisis • May 15

This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shareholders will have a reason to smile today, with the analysts making...
Artículo de análisis • May 08

Protagonist Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) last week reported its latest first-quarter results, which makes it a...
Seeking Alpha • Jan 30

Protagonist Therapeutics: Assessing The 2026 Upside For Icotrokinra And Rusfertide

Summary Protagonist Therapeutics remains a high-conviction buy, driven by late-stage assets icotrokinra and rusfertide approaching regulatory milestones in 2026. PTGX’s robust cash position of $678.8 million provides a runway through 2028, supporting aggressive R&D and upcoming commercialization efforts. Both icotrokinra and rusfertide have demonstrated strong efficacy and safety in pivotal trials, with regulatory submissions underway and significant market opportunities ahead. Valuation is premium at 21x EV/sales, reflecting high investor expectations for late-stage pipeline success; downside risk remains if approvals falter. Read the full article on Seeking Alpha
Artículo de análisis • Oct 11

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues

Despite an already strong run, Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shares have been powering on, with a gain...
Artículo de análisis • Jun 13

Subdued Growth No Barrier To Protagonist Therapeutics, Inc. (NASDAQ:PTGX) With Shares Advancing 27%

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shareholders would be excited to see that the share price has had a...
Seeking Alpha • Mar 11

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

Summary Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotrokinra, a first-in-class IL-23 receptor agonist, shows promise in treating ulcerative colitis and plaque psoriasis, potentially shifting treatment paradigms in both of these indications. Financially stable with $559.2 million in cash and recent milestone payments, Protagonist can fund operations through 2028, reducing financial risk. Future PTGX prospects include expanding icotrokinra's use to Crohn's Disease and initiating phase 1 study for PN-881, targeting immune-mediated disorders like hidradenitis suppurativa. Read the full article on Seeking Alpha
Seeking Alpha • Jan 13

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Summary Positive results achieved from both ICONIC studies using JNJ-2113 for the treatment of patients with moderate-to-severe plaque psoriasis; Superiority study is data expected in Q2 of 2025. Topline results from the phase 3 VERIFY study, using rusfertide for the treatment of patients with polycythemia vera, expected in Q1 of 2025. The global Polycythemia vera market size is expected to grow to $2.03 billion by 2032. The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027. Read the full article on Seeking Alpha
Seeking Alpha • Oct 16

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Summary Today, we circle back to the clinical stage of biopharma Protagonist Therapeutics, Inc., whose stock has tripled over the past year. The company has two late-stage drug candidates that are partnered with Takeda and Johnson & Johnson, respectively. If pivotal trials turn out to be successful, both drugs could be approved in 2026. Still more upside in this rally? An updated analysis of Protagonist Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Summary Protagonist Therapeutics' stock has experienced significant volatility over the past three years, with multiple setbacks and recoveries. The company's lead drug candidate, Rusfertide, indicated for polycythemia vera, faced a clinical hold from the FDA but had the hold removed in October 2021 and now looks approvable. Protagonist's joint plaque psoriasis candidate, JNJ-2113, showed positive results in a Phase 2 study, leading to a stock price increase. Both of Protagonist's lead candidates make a case for a commercial approval - although not for 2 more years at least, and there are risks, and hurdles still to be overcome. 2 Phase 3 studies must still be completed. The recently signed deal with Takeda to co-commercialise Rusfertide is a significant boost for Protagonist and has driven its market cap valuation to $1.64bn - I think that is an accurate reflection for its value for now, but may look to buy on any dips. Read the full article on Seeking Alpha
Seeking Alpha • Jun 08

Protagonist: Too Many Red Flags

Protagonist has recently faced a number of mishaps. These make the stock risky. They have a good deal of cash for now.
Seeking Alpha • Feb 01

Protagonist Is Still Being Undervalued Like There's Real Risk

Protagonist Therapeutics is currently working to tackle some serious issues with an underserved form of blood cancer. A recent cancer scare sent shockwaves through the company's valuation, and it has been almost entirely resolved. The current valuation is still a deep discount from the highs prior to the dip.

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dinesh Patel en comparación con los beneficios de Protagonist Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2026n/an/a

-US$115m

Dec 31 2025US$13mUS$716k

-US$130m

Sep 30 2025n/an/a

US$46m

Jun 30 2025n/an/a

US$52m

Mar 31 2025n/an/a

US$56m

Dec 31 2024US$9mUS$681k

US$275m

Sep 30 2024n/an/a

US$171m

Jun 30 2024n/an/a

US$170m

Mar 31 2024n/an/a

US$162m

Dec 31 2023US$7mUS$655k

-US$79m

Sep 30 2023n/an/a

-US$140m

Jun 30 2023n/an/a

-US$138m

Mar 31 2023n/an/a

-US$140m

Dec 31 2022US$6mUS$630k

-US$127m

Sep 30 2022n/an/a

-US$130m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$122m

Dec 31 2021US$6mUS$600k

-US$126m

Sep 30 2021n/an/a

-US$108m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$2mUS$565k

-US$66m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$83m

Dec 31 2019US$2mUS$545k

-US$77m

Compensación vs. Mercado: La compensación total de Dinesh($USD12.87M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD8.38M).

Compensación vs. Ingresos: La compensación de Dinesh ha aumentado mientras la empresa no es rentable.

CEO

Dinesh Patel (69 yo)

17.5yrs
Permanencia
US$12,871,506
Compensación

Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer, President and Director at Protagonist Therapeutics, Inc. since December 2008 and serves as its Secretary. He serves as Additional Non-Execu...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Dinesh Patel
CEO, President17.5yrsUS$12.87m0.45%
$ 31.6m
Asif Ali
Executive VP & CFO4.2yrsUS$3.26m0.0040%
$ 281.7k
Arturo Molina
Chief Medical Officer3.6yrsUS$4.10m0.021%
$ 1.5m
Venkat Thalladi
EVP & Chief Technical Officerless than a yearsin datossin datos
Newman Yeilding
Executive VP1.8yrssin datossin datos
Matthew Gosling
Executive VP and Chief Legal & Business Officer5.8yrssin datossin datos
Carena Spivey
Executive VP & Chief Human Resources Officer5.4yrssin datossin datos
Ashok Bhandari
EVP & Chief Discovery Officer5.4yrssin datossin datos
Carter King
Executive Vice President of Business Development5.2yrssin datossin datos
Abha Bommireddi
Executive VP & Chief of Staff5.4yrssin datossin datos
Samuel Saks
Clinical Development Advisor5.4yrssin datossin datos
5.4yrs
Permanencia media
62yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de PTGX es experimentado (5.4 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Dinesh Patel
CEO, President17.5yrsUS$12.87m0.45%
$ 31.6m
Harlan Weisman
Clinical Advisor11.4yrssin datossin datos
Lewis Williams
Independent Director9yrsUS$431.82k0.0080%
$ 563.4k
Chaitan Khosla
Chairman of Scientific Advisory Board11.4yrsUS$188.07ksin datos
Harold Selick
Independent Chairman17.3yrsUS$428.07k0.090%
$ 6.4m
William Waddill
Independent Director9.9yrsUS$431.82k0.0080%
$ 563.4k
Charles Craik
Scientific Advisorno datasin datossin datos
Mark Gallop
Scientific Advisorno datasin datossin datos
Wayne Lencer
Clinical Advisorno datasin datossin datos
Aida Habtezion
Clinical Advisorno datasin datossin datos
Ellen Scherl
Clinical Advisorno datasin datossin datos
Bryan Giraudo
Independent Director8.1yrsUS$431.82k0.016%
$ 1.1m
11.4yrs
Permanencia media
69yo
Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de PTGX son experimentados ( 11.4 años antigüedad media).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/06/12 23:46
Precio de las acciones al final del día2026/06/12 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Protagonist Therapeutics, Inc. está cubierta por 19 analistas. 12 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Etzer DaroutBarclays
Evan SeigermanBMO Capital Markets Equity Research
Timothy ChiangCapital One Securities, Inc.